Novartis's Zelnorm Enters Restricted Access Program

Law360, New York (July 27, 2007, 12:00 AM EDT) -- A few months after the U.S. Food and Drug Administration ordered it pulled from the market amid concerns about causing heart problems, Novartis AG's controversial drug Zelnorm will return under a restricted access program, announced the FDA and Novartis Friday.

The FDA has approved Zelnorm as a treatment investigational new drug. Women younger than 55 who suffer from either bowel syndrome with constipation or chronic idiopathic constipation for whom a doctor deems the drug medically necessary may consent to receive it, according to the FDA and...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.